We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presenting at Cowen Healthcare Conference

8 Mar 2018 07:00

RNS Number : 0452H
Realm Therapeutics PLC
08 March 2018
 

Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

 

MALVERN, PA, March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the Cowen and Company 38th Annual Health Care Conference, on Tuesday, March 13, 2018 at 10:00 a.m. ET at the Boston Marriott Copley Place. 

 

A live and archived webcast of the Cowen presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation will be available on March 13 on the Company's website at www.realmtx.com

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and to change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in Acne and additional Dermatology and Ophthalmology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAPDXELAPEFF
Date   Source Headline
4th Jun 20144:46 pmRNSPublication of Circular
4th Jun 20147:00 amRNSSale of Endoscopy Business
14th May 20147:00 amRNSInterim Management Statement
24th Apr 20147:00 amRNSFinal Results
10th Apr 20147:00 amRNSNotice of Results
19th Feb 201411:22 amRNSBlocklisting Interim Review
18th Feb 20147:00 amRNSTrading Statement
13th Feb 20147:00 amRNSMiddle East Wound Care Marketing Agreement
7th Nov 20137:00 amRNSRe Agreement
6th Nov 20138:50 amRNSHolding(s) in Company
4th Nov 201310:03 amRNSHolding(s) in Company
1st Nov 20137:00 amRNSDirector/PDMR Shareholding
28th Oct 20137:00 amRNSInterim Management Statement
22nd Oct 20137:00 amRNSLaunches New Animal Health Wound Product NovaZo
15th Oct 20137:00 amRNSDirector Details
11th Oct 20137:00 amRNSReached agreement with Misonix
27th Sep 20137:00 amRNSValue Creation Plan Update
6th Sep 20131:58 pmRNSDirector Dealing
16th Aug 20133:24 pmRNSDirector Dealing
12th Aug 20131:59 pmRNSShare Option Grant
8th Aug 20137:00 amRNSHalf Yearly Report
2nd Aug 20137:00 amRNSBlocklisting Interim Review
17th Jul 20137:00 amRNSNotice of Results
28th Jun 20137:00 amRNSTotal Voting Rights
26th Jun 201311:19 amRNSResult of AGM
20th Jun 20137:00 amRNSPuriCore signs $13.5 million US deal
19th Jun 20131:16 pmRNSAGM Update
11th Jun 20133:08 pmRNSHolding(s) in Company
11th Jun 20133:06 pmRNSHolding(s) in Company
5th Jun 20131:13 pmRNSHolding(s) in Company - Replacement
5th Jun 20131:10 pmRNSHolding(s) in Company - Replacement
4th Jun 20133:04 pmRNSHolding(s) in Company
4th Jun 20133:01 pmRNSHolding(s) in Company
17th May 20137:46 amRNSInterim Management Statement
14th May 20137:00 amRNSBoard Changes
2nd May 20137:00 amRNSShare Option Grant
1st May 20137:00 amRNSTotal Voting Rights
30th Apr 20137:00 amRNSFinal Results
17th Apr 20131:57 pmRNSNotice of Results
8th Apr 20137:00 amRNSPuriCore Signs Major US Deal
3rd Apr 20137:00 amRNSPuriCore Signs Vashe Marketing Agreement
7th Mar 20137:00 amRNSTrading Update
6th Mar 20137:00 amRNSPuriCore Partners with Onset Dermatologics
5th Mar 20137:00 amRNSBoard and Organisational Changes
15th Feb 20135:20 pmRNSBlocklisting Interim Review
14th Feb 20137:00 amRNSFDA 510(k) Clearance
12th Feb 20136:01 pmRNSShare Option Grant and Blocklisting Update
7th Feb 20135:39 pmRNSApplication for Blocklisting
1st Feb 20134:40 pmRNSSecond Price Monitoring Extn
1st Feb 20134:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.